Juvenile Arthritis News

Pediatric rheumatology patients could be considered ready to transfer to adult care if they score greater than 4 on the Transition Readiness Assessment Questionnaire, according to data published in Rheumatology.

The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.

New definitions of remission specific to childhood systemic lupus erythematosus promote cessation of corticosteroids and could enable combined child-adult treat-to-target studies, according to an analysis published in Clinical Immunology.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

The FDA has approved a Benlysta autoinjector for children aged 5 years and older with systemic lupus erythematosus, enabling at-home administration for the first time, according to a press release from the manufacturer.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

Patients with immune-mediated diseases have higher rates of adverse pregnancy outcomes such as preeclampsia and pre-term delivery, with lupus and systemic sclerosis conferring the largest risks, according to data published in Rheumatology.

Nearly 40% of children with oligoarticular juvenile idiopathic arthritis treated with intra-articular corticosteroids required no additional therapy, according to data published in Arthritis Research & Therapy.

The FDA has authorized the first chimeric antigen receptor T-cell clinical trial for children with systemic lupus erythematosus.